Cargando…

Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

OBJECTIVES: To evaluate the safety and effectiveness of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA) in real-world clinical settings in Japan. METHODS: Paediatric patients with sJIA initiating TCZ between April 2008 and February 2012 and those previously enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokota, Shumpei, Itoh, Yasuhiko, Morio, Tomohiro, Origasa, Hideki, Sumitomo, Naokata, Tomobe, Minako, Tanaka, Kunihiko, Minota, Seiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013079/ https://www.ncbi.nlm.nih.gov/pubmed/26644233 http://dx.doi.org/10.1136/annrheumdis-2015-207818

Ejemplares similares

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
por: Koike, Takao, et al.
Publicado: (2011)

Tocilizumab-effects on growth impairment in systemic juvenile idiopathic arthritis
por: Miyamae, Takako, et al.
Publicado: (2011)

Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan
por: Mori, Masaaki, et al.
Publicado: (2008)

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis
por: Murakami, Miho, et al.
Publicado: (2012)

Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab
por: De Benedetti, Fabrizio, et al.
Publicado: (2014)

Gender differences in SLE: report from a cohort of 417 Caucasian patients
por: Trentin, Francesca, et al.
Publicado: (2023)

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
por: Nakaoka, Yoshikazu, et al.
Publicado: (2018)

Postmarketing observational study on the safety of 2021/2022 and 2022/2023 influenza vaccination campaigns in Italy: TheShinISS-Vax|Flu study protocol
por: Spila Alegiani, Stefania, et al.
Publicado: (2023)

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2015)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

PReS-FINAL-2110: Tocilizumab for patients with oligoarticular juvenile idiopathic arthritis refractory to conventional therapy
por: Sato, T, et al.
Publicado: (2013)

Current topics in catecholaminergic polymorphic ventricular tachycardia
por: Sumitomo, Naokata
Publicado: (2016)

Neo atrioventricular conduction after Bjork operation
por: Sumitomo, Naokata
Publicado: (2012)

Séminaire Bourbaki : exposés 400–417
por: Dold, A, et al.
Publicado: (1973)

Analysis of non-respondent pregnant women who were registered in the Japan Environment and Children’s Study: a longitudinal cohort study
por: Kigawa, Mika, et al.
Publicado: (2019)

Factors of non-responsive or lost-to-follow-up Japanese mothers during the first year post partum following the Japan Environment and Children’s Study: a longitudinal cohort study
por: Kigawa, Mika, et al.
Publicado: (2019)

Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis
por: Herlin, Troels
Publicado: (2010)

Safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis
por: Horneff, G, et al.
Publicado: (2015)

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
por: Mariette, Xavier, et al.
Publicado: (2018)

Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study
por: Clowse, Megan EB, et al.
Publicado: (2017)

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
por: Burmester, Gerd R, et al.
Publicado: (2016)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
por: Yazılıtaş, Fatma, et al.
Publicado: (2020)

Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis
por: He, Tingyan, et al.
Publicado: (2023)

Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
por: Iannone, Claudia, et al.
Publicado: (2023)

Incidence of Gastrointestinal Perforations in Patients with Rheumatoid Arthritis Treated with Tocilizumab from Clinical Trial, Postmarketing, and Real-World Data Sources
por: Monemi, Sharareh, et al.
Publicado: (2016)

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
por: Imagawa, Tomoyuki, et al.
Publicado: (2012)

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
por: Ramiro, Sofia, et al.
Publicado: (2020)

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Shimizu, Masaki, et al.
Publicado: (2020)

Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis
por: Alexeeva, E, et al.
Publicado: (2011)

The use of tocilizumab in a child with systemic onset juvenile idiopathic arthritis and ganglioneuroblastoma
por: Goran, Ristic, et al.
Publicado: (2011)

Efficacy and safety of tocilizumab in european children with systemic onset juvenile idiopathic arthritis
por: Nemiche, O, et al.
Publicado: (2011)

Effects of antirheumatic treatment with tocilizumab on longitudinal growth in children with juvenile idiopathic arthritis
por: Alexeeva, Ekaterina, et al.
Publicado: (2014)

Tocilizumab therapy in systemic juvenile idiopathic arthritis – lessons of real clinical practice
por: Kaleda, Maria I, et al.
Publicado: (2014)

Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience
por: Roszkiewicz, Justyna, et al.
Publicado: (2018)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
por: Hara, Ryoki, et al.
Publicado: (2019)

Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open‐label, single‐arm, phase 3, and postmarketing clinical study
por: Onodera, Masafumi, et al.
Publicado: (2023)

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2015)

Systemic juvenile idiopathic arthritis: frequency and long-term outcome in Western Australia
por: Nossent, Johannes C., et al.
Publicado: (2023)

Disease history and risk of comorbidity in women's life course: a comprehensive analysis of the Japan Nurses’ Health Study baseline survey
por: Nagai, Kazue, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_q068u1g0gfiiqlnr54u22bqc3r